Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis
Version of Record online: 30 SEP 2013
© 2013, The American College of Clinical Pharmacology
The Journal of Clinical Pharmacology
Volume 53, Issue 12, pages 1240–1251, December 2013
How to Cite
Chakraborty, A., Van, L. M., Skerjanec, A., Floch, D., Klein, U. R., Krammer, G., Sunkara, G. and Howard, D. (2013), Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. Journal of Clinical Pharma, 53: 1240–1251. doi: 10.1002/jcph.162
- Issue online: 14 NOV 2013
- Version of Record online: 30 SEP 2013
- Manuscript Accepted: 13 AUG 2013
- Manuscript Received: 10 MAY 2013
- Novartis Pharmaceuticals Corporation
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Figure S1. Relationship between CrCl and canakinumab clearance (estimated by the PK-binding model using the post hoc option of NONMEM) in gouty arthritis patients (line represents the fitting by a power function). CrCl, creatinine clearance; PK, pharmacokinetic.
Table S1. Summary of Canakinumab Clinical Study Designs
Table S2. Summary of Baseline Demographic Parameters
Table S3. Institutional Review Board or Ethics Committee Listings by Center Number
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.